Repro Med Systems Stock Net Asset
| KRMD Stock | USD 3.20 0.23 7.74% |
Repro Med Systems fundamentals help investors to digest information that contributes to Repro Med's financial success or failures. It also enables traders to predict the movement of Repro Stock. The fundamental analysis module provides a way to measure Repro Med's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Repro Med stock.
Repro | Net Asset |
Repro Med Systems Company Net Asset Analysis
Repro Med's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Repro Med Net Asset | 28.46 M |
Most of Repro Med's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Repro Med Systems is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Repro Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Repro Med is extremely important. It helps to project a fair market value of Repro Stock properly, considering its historical fundamentals such as Net Asset. Since Repro Med's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Repro Med's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Repro Med's interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Repro Total Assets
Total Assets |
|
Based on the recorded statements, Repro Med Systems has a Net Asset of 28.46 M. This is much higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Repro Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Repro Med's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Repro Med could also be used in its relative valuation, which is a method of valuing Repro Med by comparing valuation metrics of similar companies.Repro Med is currently under evaluation in net asset category among its peers.
Repro Med ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Repro Med's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Repro Med's managers, analysts, and investors.Environmental | Governance | Social |
Repro Med Institutional Holders
Institutional Holdings refers to the ownership stake in Repro Med that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Repro Med's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Repro Med's value.| Shares | Boothbay Fund Management, Llc | 2024-06-30 | 267.2 K | Northern Trust Corp | 2024-06-30 | 260.6 K | Blackrock Inc | 2024-06-30 | 186.8 K | State Street Corp | 2024-06-30 | 126.7 K | Alpine Partners Vi, Llc | 2024-06-30 | 107.2 K | Washington Trust Co | 2024-06-30 | 100 K | Pnc Financial Services Group Inc | 2024-06-30 | 97 K | Jane Street Group Llc | 2024-06-30 | 93.9 K | Citadel Advisors Llc | 2024-06-30 | 92.5 K | First Light Asset Management, Llc | 2024-06-30 | 5 M | Vanguard Group Inc | 2024-06-30 | 1.8 M |
Repro Fundamentals
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0.38) % | ||||
| Operating Margin | (0.14) % | ||||
| Current Valuation | 129.7 M | ||||
| Shares Outstanding | 45.86 M | ||||
| Shares Owned By Insiders | 6.29 % | ||||
| Shares Owned By Institutions | 54.41 % | ||||
| Number Of Shares Shorted | 486.92 K | ||||
| Price To Earning | 11.56 X | ||||
| Price To Book | 7.28 X | ||||
| Price To Sales | 4.42 X | ||||
| Revenue | 28.52 M | ||||
| Gross Profit | 15.37 M | ||||
| EBITDA | (9.4 M) | ||||
| Net Income | (13.74 M) | ||||
| Cash And Equivalents | 18.27 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 4.45 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 5.40 X | ||||
| Book Value Per Share | 0.41 X | ||||
| Cash Flow From Operations | (4.89 M) | ||||
| Short Ratio | 5.39 X | ||||
| Earnings Per Share | (0.25) X | ||||
| Target Price | 3.6 | ||||
| Number Of Employees | 82 | ||||
| Beta | 0.41 | ||||
| Market Capitalization | 136.19 M | ||||
| Total Asset | 28.46 M | ||||
| Retained Earnings | (23.31 M) | ||||
| Working Capital | 15.8 M | ||||
| Current Asset | 2.54 M | ||||
| Current Liabilities | 516.46 K | ||||
| Net Asset | 28.46 M |
About Repro Med Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Repro Med Systems's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Repro Med using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Repro Med Systems based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Repro Med Systems is a strong investment it is important to analyze Repro Med's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Repro Med's future performance. For an informed investment choice regarding Repro Stock, refer to the following important reports:Check out Repro Med Piotroski F Score and Repro Med Altman Z Score analysis. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repro Med. If investors know Repro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repro Med listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (0.25) | Revenue Per Share 0.674 | Quarterly Revenue Growth 0.215 | Return On Assets (0.14) |
The market value of Repro Med Systems is measured differently than its book value, which is the value of Repro that is recorded on the company's balance sheet. Investors also form their own opinion of Repro Med's value that differs from its market value or its book value, called intrinsic value, which is Repro Med's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repro Med's market value can be influenced by many factors that don't directly affect Repro Med's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repro Med's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repro Med is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repro Med's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.